Veradermics (MANE) Cash & Equivalents (2024 - 2026)

Veradermics (MANE) posted Cash & Equivalents of $168.4 million for Q1 2026, up 673.74% on a QoQ basis from $21.8 million in Q4 2025.

Veradermics (MANE) Cash & Equivalents (2024 - 2026) Analysis & Trends

Veradermics' Cash & Equivalents history runs 3 years deep, the most recent figure standing at $168.4 million for Q1 2026.

Quarterly Cash & Equivalents changed N/A year-over-year to $168.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $168.4 million (changed N/A YoY) and the FY2025 annual result came in at $21.8 million, down 59.0% from the prior year.
Cash & Equivalents was $168.4 million for Q1 2026 at Veradermics, up from $21.8 million in the prior quarter.
Across five years, Cash & Equivalents topped out at $168.4 million in Q1 2026 and bottomed at $21.8 million in Q4 2025.
A 3-year average of $81.1 million and a median of $53.1 million in 2024 frame the typical range for Cash & Equivalents.
Peak annual rise in Cash & Equivalents reached 59.0% in 2025, while the deepest fall reached 59.0% in 2025.
Veradermics' Cash & Equivalents stood at $53.1 million in 2024, then tumbled by 59.0% to $21.8 million in 2025, then jumped by 673.74% to $168.4 million in 2026.
Business Quant data shows MANE's Cash & Equivalents at $168.4 million in Q1 2026, $21.8 million in Q4 2025, and $53.1 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash & Equiv. (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	82.45 Mn
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	61.40 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	4.79 Bn
4	NuCana	279.75 Bn	279.75 Bn	-	32.26 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	5.49 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	2.96 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	3.58 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	440.94 Mn
10	Veradermics	2.63 Bn	2.63 Bn	-	168.41 Mn

Download Data